CBD Oil for Endometriosis Pain: Mechanisms, Evidence, and Dosing
By PureCraft Editorial Team | PureCraft CBD | Updated October 2026
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Endometriosis is a complex chronic condition requiring diagnosis and management by a qualified gynecologist or pelvic pain specialist. CBD is not a substitute for hormonal therapy, surgical evaluation, or any prescribed treatment. Always consult your healthcare provider before adding CBD to your regimen, particularly if you are taking hormonal contraceptives, GnRH agonists, or other medications. The FDA has not approved CBD for treating endometriosis or any gynecological condition.
Endometriosis is one of the most painful and least-understood conditions affecting women of reproductive age — and one of the most underserved. Average diagnostic delay runs seven to ten years. Treatments remain limited: NSAIDs that work poorly for severe disease, hormonal therapies that suppress cycles but carry their own burdens, and surgery that offers relief but not always a cure.
Against this backdrop, research into CBD oil for endometriosis pain has attracted serious scientific attention — not because CBD is a miracle cure, but because endometriosis pain operates through at least four distinct biological mechanisms, and CBD interacts with all of them. This article breaks down each mechanism, reviews the clinical and preclinical evidence, provides a practical dosing framework, and flags the drug interactions every endo patient needs to know before trying CBD.
What Is Endometriosis — and Why Is the Pain So Complex?
Endometriosis occurs when endometrial-like tissue — the type that lines the inside of the uterus — grows outside the uterus. Common sites include the peritoneum (the lining of the pelvic cavity), the ovaries, fallopian tubes, uterosacral ligaments, bladder, and rectosigmoid colon. In severe cases, lesions extend to the diaphragm and even the lungs. This ectopic tissue responds to the same hormonal cycles as normal endometrium: it proliferates, breaks down, and bleeds — but with nowhere to go, triggering inflammation, scarring, and adhesion formation.
Approximately 190 million women worldwide live with endometriosis — roughly 10% of those of reproductive age. Despite its prevalence, the condition carries a diagnostic delay of seven to ten years from symptom onset to confirmed diagnosis, largely because dysmenorrhea is often dismissed as normal menstrual pain.
The Three Subtypes
Endometriosis is not a single disease but a spectrum of three distinct subtypes with very different pain profiles:
- Superficial peritoneal endometriosis: Lesions on the surface of the peritoneum. Common, visible at laparoscopy, and responsible for cyclical pain driven primarily by inflammation.
- Ovarian endometrioma (chocolate cysts): Cysts containing old blood inside the ovary. Can cause pelvic pressure, dyspareunia, and ovarian reserve reduction.
- Deep infiltrating endometriosis (DIE): Lesions that penetrate more than 5mm into peritoneal tissue, often involving the uterosacral ligaments, pouch of Douglas, rectovaginal septum, bowel, or bladder. DIE is the most painful subtype and the least responsive to anti-inflammatory treatment alone — because its pain mechanism goes well beyond inflammation.
Associated Conditions: The Visceral Hypersensitivity Cluster
Endometriosis rarely travels alone. A significant proportion of women with endo also experience adenomyosis (endometrial tissue within the uterine muscle), interstitial cystitis (painful bladder syndrome), irritable bowel syndrome, and fibromyalgia. Russo (2016) proposed that this cluster — endo, fibromyalgia, IBS, and migraine — shares an underlying "Clinical Endocannabinoid Deficiency" (CECD), where systemic ECS tone is inadequate to modulate visceral and somatic pain. This framework has important implications for why CBD may address multiple overlapping pain conditions simultaneously. For a parallel discussion, see our article on CBD oil for fibromyalgia.
Four Pain Mechanisms — and How CBD oil Addresses Each
This is the core of why endometriosis pain is biologically distinct from ordinary menstrual cramping — and why treatments that address only one mechanism (like NSAIDs for prostaglandins) often provide incomplete relief. CBD's pharmacological profile spans all four drivers.
1. Peritoneal Inflammation and Prostaglandin Overproduction
Ectopic lesions behave like miniature inflammatory reactors. They stimulate peritoneal macrophages to produce elevated levels of prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) — the same prostanoids that drive menstrual cramping, but in quantities far exceeding normal menstruation and in locations that inflame the entire pelvic peritoneum. This explains why NSAIDs provide some relief (by blocking COX-mediated prostaglandin synthesis) but are insufficient for moderate-to-severe disease, particularly DIE.
CBD engages the CB2 receptor, which is highly expressed on macrophages. CB2 activation suppresses macrophage-derived inflammatory mediators, including prostaglandin synthesis and TNF-α release. This mechanism overlaps with but is distinct from COX inhibition, suggesting CBD and NSAIDs may offer complementary, additive anti-inflammatory effects in endometriosis. Women managing this type of cramping-dominant pain may also benefit from reading our overview of CBD oil for menstrual cramps.
2. Nerve Infiltration of Lesions (Neurogenesis Within Endo Tissue)
This mechanism is specific to endometriosis — particularly DIE — and explains why endo pain is categorically different from simple cramping. DIE lesions are actively innervated: sensory and sympathetic nerve fibers grow directly INTO lesion tissue through a process called lesion neurogenesis. The lesion becomes, in effect, a pain-generating structure with its own nerve supply. These lesion-infiltrating nerve fibers express TRPV1 (the transient receptor potential vanilloid 1 channel), the same receptor activated by capsaicin and heat — one of the primary channels for transmitting pelvic pain signals.
CBD is a potent TRPV1 agonist that ultimately desensitizes the receptor, reducing its ability to fire pain signals. When CBD desensitizes TRPV1 on lesion-infiltrating nerve fibers, it directly targets a pain structure that is unique to endometriosis. This is not a generic anti-inflammatory effect — it is anatomically specific to the neurogenic component of DIE pain. This same mechanism underlies CBD's utility in neuropathic pain conditions more broadly.
3. Central Sensitization and Spinal Wind-Up
Chronic pelvic pain — sustained over months or years as is typical in undiagnosed endometriosis — induces central sensitization: structural and functional changes in spinal cord pain processing that lower the threshold for pain signals. This is sometimes called "spinal wind-up." The clinical consequences are significant: allodynia (pain from stimuli that should not be painful, such as light touch to the lower abdomen), widespread pelvic hypersensitivity, and — critically — pain that persists even after laparoscopic removal of lesions, because the central nervous system has been rewired.
CBD modulates central sensitization through two mechanisms: potentiation of glycine receptors (GlyRα3), which provide inhibitory tone in the spinal cord, and modulation of NMDA receptor activity, which drives spinal wind-up. By addressing the central sensitization component, CBD may help with residual pain after surgical excision — a therapeutic gap that current post-surgical pain management often fails to fill. This overlaps with the central mechanisms covered in our CBD oil for pelvic pain guide.
4. Endocannabinoid System Dysregulation in Endometriosis
Perhaps the most compelling evidence for CBD's relevance to endometriosis comes from research demonstrating that the ECS itself is dysregulated in endo patients. Sanchez et al. (2016), published in Human Reproduction, found that women with endometriosis exhibit significantly reduced CB1 receptor expression in their eutopic endometrium (the normal uterine lining) and altered anandamide (AEA) levels in peritoneal fluid. Additionally, fatty acid amide hydrolase (FAAH) — the enzyme that breaks down anandamide — is elevated in endometriosis lesions, causing faster-than-normal AEA breakdown and lower endocannabinoid tone precisely where it is most needed.
CBD inhibits FAAH, which slows AEA breakdown and restores endocannabinoid tone. This means CBD is not simply adding an external cannabinoid — it is compensating for a documented deficiency in the endogenous pain-regulating system of women with endometriosis. This is endometriosis-specific ECS evidence, distinct from generic CBD pain research.
Dyspareunia: Pain During Sex from Endometriosis
Deep dyspareunia — pain during deep penetration — is reported by up to 50% of women with endometriosis and is most severe when DIE lesions involve the uterosacral ligaments, pouch of Douglas, or rectovaginal septum. Unlike superficial dyspareunia (pain at entry), deep dyspareunia in endo is driven by mechanical pressure on heavily innervated lesions during intercourse, compounded by the nerve sensitization and central sensitization described above.
Systemic CBD — whether via sublingual CBD oil or softgels — works on the nerve sensitization component through TRPV1 desensitization and CB2-mediated anti-inflammation. Topically, applying our nano CBD muscle and joint cream to the lower abdomen and sacral area 30–60 minutes before intercourse may help reduce surface-level tension and sensitization in the overlying tissue. While topical application does not reach deep pelvic structures directly, the supporting evidence for transdermal CBD penetration (Hammell 2016) suggests meaningful absorption through skin — and many patients report subjective benefit from this approach.
Bowel and Bladder Endometriosis
DIE involving the rectosigmoid colon causes cyclical rectal pain, painful defecation (dyschezia), diarrhea or constipation around menstruation, and rectal bleeding in severe cases. Bladder endometriosis produces cyclical urinary urgency, frequency, and suprapubic pain. Both presentations involve visceral hypersensitivity — an amplified pain response from the enteric and lower urinary tract nervous systems that shares mechanisms with IBS and interstitial cystitis.
CB1 receptors are heavily expressed on enteric neurons throughout the gastrointestinal tract, where they modulate gut motility, visceral pain signaling, and intestinal inflammation. CBD's modulation of ECS tone in the gut — combined with its anti-inflammatory actions — offers a rationale for addressing the GI and urinary symptoms of DIE. For more on the visceral pain dimension of pelvic pain, including bladder and bowel involvement, see our dedicated guide.
Using CBD oil Alongside Hormonal Therapies for Endometriosis
Most women with endometriosis are prescribed hormonal therapies — combined oral contraceptive pills (OCP), progestins (including dienogest, the most widely used dedicated endo treatment outside the US), or GnRH agonists such as leuprolide (Lupron). These therapies suppress ovulation and reduce the hormonal stimulation of ectopic lesions. CBD does not replace any of these treatments.
Important: CBD Does Not Replace Hormonal Therapy or Surgical Evaluation
CBD addresses pain mechanisms but does not suppress the hormonal stimulation of endometriosis lesions, does not treat the underlying pathology, and is not a substitute for hormonal therapy or laparoscopic excision where indicated. Women with suspected deep infiltrating endometriosis should pursue formal surgical evaluation regardless of CBD use. Pain management with CBD is complementary, not curative.
CYP3A4 and Estrogen Metabolism
One important pharmacokinetic consideration: estrogen — whether endogenous or from combined OCPs — is metabolized primarily by CYP3A4. CBD inhibits CYP3A4 at sufficient doses, which theoretically could mildly alter estrogen metabolism. The clinical significance at typical CBD doses (10–50mg/day) is uncertain and likely minor, but women on combined OCPs should monitor for any changes in cycle regularity or spotting and report these to their gynecologist. Dienogest (Visanne) is also metabolized by CYP3A4, so the same monitoring applies. GnRH agonists like leuprolide are peptide-based and not CYP-metabolized — no known pharmacokinetic interaction with CBD.
Dosing Framework for Endometriosis Pain
Endometriosis pain is not constant — it cycles, flares, and varies by subtype. A responsive dosing strategy accounts for this variability.
| Use Case | Suggested Dose | Format | Timing |
|---|---|---|---|
| Menstrual flare / dysmenorrhea (5-day window) | 25–50mg 2–3×/day | CBD Oil or gummies | Begin 1–2 days before expected onset |
| Chronic pelvic pain maintenance | 15–30mg 2×/day | Softgels for consistent dosing | Morning and evening, with food |
| Dyspareunia support | 25mg systemic + topical | Oil + topical cream to lower abdomen | 60–90 min before intercourse |
| Sleep disruption during flare | 25–50mg CBD + melatonin | CBD+CBN+melatonin sleep gummies | 30–60 min before bed |
| Post-laparoscopic recovery support | 25–50mg 2×/day | Full-spectrum gummies or oil | As complement to prescribed post-op pain protocol; clearance from surgeon required |
Nano-emulsified CBD formulas offer faster onset and higher bioavailability than standard CBD oil — onset typically 15–30 minutes vs. 60–90 minutes for standard formulations.
Drug Interaction Guide for Endometriosis Patients
The endo patient's medication list is often complex. Here is a summary of the key interactions to discuss with your prescriber.
| Medication | Interaction | Clinical Significance | Action |
|---|---|---|---|
| NSAIDs (ibuprofen, naproxen) | Minor CYP2C9 competition | Low — NSAIDs are standard co-treatment; additive anti-inflammatory benefit likely | Generally safe; standard monitoring |
| Combined oral contraceptive pill (OCP) | Mild CYP3A4 inhibition by CBD; estrogen is CYP3A4 substrate | Low-moderate — theoretically may affect estrogen metabolism at higher CBD doses | Monitor for breakthrough bleeding; inform gynecologist |
| Dienogest (progestin for endo) | CYP3A4 substrate; mild CBD inhibition | Low-moderate — monitor for any side effect changes | Discuss with prescribing gynecologist before adding CBD |
| GnRH agonists (leuprolide/Lupron) | Peptide-based; not CYP-metabolized | Minimal known pharmacokinetic interaction | Inform prescriber; no dose adjustment expected |
| Opioids (prescribed for severe DIE) | CYP3A4 inhibition may increase opioid plasma levels | Moderate to high — additive CNS depression risk | Mandatory prescriber consultation; do not combine without medical supervision |
| Duloxetine / antidepressants (fibromyalgia overlap) | CYP2D6 inhibition by CBD may elevate duloxetine levels | Moderate | Monitor for increased SNRI side effects; prescriber notification required |
Full-Spectrum vs. Broad-Spectrum CBD oil for Endometriosis
The entourage effect — the hypothesis that cannabinoids, terpenes, and minor phytocannabinoids work synergistically — is particularly relevant for a complex pain condition like endometriosis. Full-spectrum products retain trace THC (under 0.3%) alongside CBD, CBG, CBN, and terpenes like myrcene and beta-caryophyllene. Beta-caryophyllene is a dietary terpene that acts as a selective CB2 agonist — directly relevant to the peritoneal inflammatory mechanism in endo.
For women who cannot use THC-containing products (due to drug testing, sensitivity, or personal preference), our broad-spectrum gummies and broad-spectrum CBD oil deliver the full cannabinoid profile minus THC. For those open to full-spectrum options, our full-spectrum berry gummies provide the complete plant matrix. On days when immune support is a priority alongside pain management, our elderberry CBD gummies combine broad-spectrum CBD with elderberry's anti-inflammatory polyphenols.
Endometriosis, Anxiety, and the Psychological Burden of Chronic Pain
Endometriosis carries a substantial psychological burden. Chronic pain, diagnostic invalidation, disrupted relationships, and infertility anxiety combine to produce rates of anxiety and depression significantly above population norms. Corroon and Leavens (2018) found that 62% of surveyed CBD users cited anxiety as a primary motivation. CBD's anxiolytic effects — mediated through 5-HT1A partial agonism and modulation of the amygdalar stress response — address this dimension of endometriosis that purely gynecological treatments often ignore.
Sleep disruption from pelvic pain compounds mood dysregulation. Our CBD+CBN sleep gummies with melatonin target the pain-sleep interface specifically. For more on both dimensions, see our guides on CBD for sleep and CBD for anxiety.
CBD Is Not a Substitute for Surgical Evaluation in Deep Infiltrating Endometriosis
Women with severe or progressive pelvic pain, suspected bowel or bladder involvement, infertility, or symptoms consistent with DIE require formal surgical evaluation by an endometriosis specialist. Laparoscopic excision by an experienced surgeon remains the gold standard for diagnosis and treatment of DIE. CBD may meaningfully improve pain management and quality of life, but it does not treat the underlying lesions, does not prevent disease progression, and should never be used as a reason to delay necessary surgical intervention.
Pelvic Floor Muscle Spasm in Endometriosis
A frequently overlooked dimension of endometriosis pain is secondary pelvic floor hypertonicity — chronic guarding and spasm of the pelvic floor muscles in response to ongoing pain. This creates a pain-spasm-pain cycle that persists even after hormonal or surgical intervention. CBD's muscle relaxant properties, mediated through GABA-A potentiation and TRPV1 desensitization, are directly relevant here. Our dedicated guide on CBD for muscle spasms covers the antispasmodic mechanism in detail. Topical application of CBD cream to the lower abdomen and inner thighs may support pelvic floor muscle relaxation between physical therapy sessions. For the joint pain and widespread musculoskeletal pain that often accompanies the endo-fibromyalgia overlap, see our CBD for joint pain guide.
Frequently Asked Questions
Can CBD oil help with endometriosis pain?
Evidence suggests CBD can address multiple drivers of endometriosis pain through distinct pharmacological pathways: CB2-mediated reduction of peritoneal inflammation, TRPV1 desensitization of lesion-infiltrating nerve fibers, modulation of central sensitization via glycine receptors and NMDA pathways, and FAAH inhibition that restores endocannabinoid tone documented as deficient in endo patients. A 2021 survey published in the Journal of Obstetrics and Gynaecology found that women with endometriosis rated cannabis-based medicines as highly effective for pelvic pain management (Aviram 2017 provides related survey data). CBD is not a cure and does not eliminate lesions, but for pain management and quality of life, the biological rationale is stronger for endometriosis than for most other pain conditions.
Does CBD oil affect hormones or hormonal therapy?
CBD does not directly modulate estrogen, progesterone, or LH/FSH levels. It does not mimic estrogen or act as an endocrine disruptor in the clinical evidence to date. However, CBD inhibits CYP3A4, the enzyme that metabolizes estrogen and progestins like dienogest. At typical supplemental CBD doses (10–50mg/day), this effect is mild and unlikely to be clinically significant for most women. At higher doses, it could theoretically alter hormone metabolism enough to affect cycle regularity in women on combined OCPs. Women on hormonal therapies should inform their gynecologist before starting CBD and monitor for any changes in spotting or cycle patterns.
Can I use CBD oil cream for endometriosis?
Topical CBD cream cannot reach the deep pelvic structures where endometriosis lesions reside — the peritoneum, uterosacral ligaments, and bowel are too deep for transdermal penetration. However, Hammell et al. (2016) demonstrated that transdermal CBD does penetrate skin meaningfully and produce systemic effects in a rat arthritis model. Applied to the lower abdomen, sacral area, or inner thighs, CBD cream can reduce local muscle tension and surface-level nerve sensitization, which many women find helpful as a complementary approach alongside systemic CBD. It is most commonly used around the menstrual flare and before intercourse. It is not a standalone treatment for endometriosis pain.
Will CBD oil help with pain during sex from endometriosis?
Deep dyspareunia in endometriosis is driven by mechanical pressure on innervated DIE lesions, nerve sensitization, and central sensitization — all of which CBD has pharmacological activity against. Survey evidence suggests women with endo who use cannabis or CBD report meaningful improvements in pain during sex, though controlled trial data is limited. A practical protocol — 25mg systemic CBD taken 60–90 minutes before intercourse, combined with topical CBD cream applied to the lower abdomen and perineal area — addresses both systemic nerve sensitization and local muscle tension. This should be considered a supportive measure, not a medical treatment for the underlying lesion driving dyspareunia.
Can CBD oil help bowel endometriosis symptoms?
CBD has well-established activity in gut pain modulation through CB1 receptors on enteric neurons and CB2 receptors on intestinal immune cells. For the dyschezia, cyclical bowel pain, and GI hypersensitivity associated with rectosigmoid DIE, CBD's gut ECS modulation and anti-inflammatory effects provide a relevant mechanism. The IBS-endo overlap — where visceral hypersensitivity affects both gynecological and GI pain — is one of the clearest presentations of what Russo (2016) describes as Clinical Endocannabinoid Deficiency. CBD does not treat bowel endometriosis lesions and does not replace evaluation for bowel involvement, which often requires specialized imaging and surgical planning.
How long does CBD oil take to help endometriosis pain?
Response timeline depends on which pain mechanism dominates and which CBD format is used. For acute menstrual cramping, nano-emulsified CBD oil taken sublingually can produce noticeable relief in 15–30 minutes. Gummies typically take 30–60 minutes. The inflammatory and nerve sensitization components respond over days to weeks of consistent use, with many users reporting progressive improvement over two to four menstrual cycles of regular dosing. Central sensitization — the most deeply rooted pain driver — may require the longest timeline to show improvement, consistent with how other treatments for central sensitization (such as SNRIs) take weeks to months to show full effect. Start low, titrate up over 2–3 weeks, and evaluate across at least two menstrual cycles before assessing effectiveness.
Is full-spectrum or broad-spectrum CBD oil better for endometriosis?
Both have merit for endometriosis. Full-spectrum products include trace THC alongside CBD, CBG, CBN, and terpenes — and the entourage effect argument is particularly strong for a multi-mechanism pain condition like endo. Beta-caryophyllene (a CB2-active terpene retained in full-spectrum and many broad-spectrum extracts) directly targets the peritoneal inflammatory mechanism. Broad-spectrum products eliminate THC while retaining most other cannabinoids, making them suitable for women subject to drug testing or THC sensitivity. For the fibromyalgia and widespread pain overlap, some evidence suggests full-spectrum may offer superior effect. Ultimately, individual response varies — many women cycle between the two depending on the phase of their condition.
Can CBD oil reduce endometriosis lesion growth?
Preclinical evidence — primarily in animal models — has shown that ECS modulation can reduce endometriotic lesion size and vascularization. CB1 and CB2 activation in mouse models has been associated with reduced lesion proliferation, reduced angiogenesis (new blood vessel formation that feeds lesions), and reduced nerve fiber density within lesions. However, this data has not been replicated in human trials, and it would be premature to claim CBD reduces lesion burden in women. The most honest characterization is: CBD may address the pain mechanisms generated by existing lesions, and the ECS may play a role in lesion biology, but CBD is not a confirmed anti-endometriotic agent in humans.
Can I take CBD oil with my birth control pill?
At typical CBD supplement doses (10–50mg/day), the interaction with combined OCPs is likely to be minor. CBD inhibits CYP3A4 — one of the pathways for estrogen and progestin metabolism — which theoretically could modestly increase the systemic exposure to OCP hormones or, in some cases, reduce their metabolism depending on individual CYP variation. The clinical consequence at low CBD doses is probably minimal, but women on OCPs should inform their gynecologist, start with a low CBD dose, and watch for any changes in breakthrough bleeding, spotting, or cycle irregularity that weren't present before adding CBD. At higher CBD doses (above 100mg/day), the interaction may become more clinically relevant.
Does CBD oil help the anxiety and depression that comes with endometriosis?
Yes — CBD's anxiolytic and mood-modulating effects, mediated through 5-HT1A partial agonism and hippocampal neurogenesis support, are well-documented in the preclinical literature and supported by large surveys. For a condition like endometriosis, where psychological distress is an integral part of the disease burden rather than a secondary complication, CBD's dual action on pain and mood represents a meaningful advantage over treatments that target only one dimension. The sleep disruption caused by pelvic pain further compounds anxiety and mood — using CBD specifically formulated for sleep during flares addresses all three dimensions simultaneously. CBD should be used alongside, not instead of, mental health support for women experiencing significant depression or anxiety.
Related Articles
- CBD Oil for Menstrual Cramps — prostaglandins, cramping mechanisms, and CBD's role in dysmenorrhea
- CBD Oil for Pelvic Pain — comprehensive guide to pelvic pain types including bladder and bowel involvement
- CBD Oil for Fibromyalgia — the visceral hypersensitivity cluster: fibromyalgia, IBS, and central sensitization
- CBD Oil for Neuropathic Pain — TRPV1, nerve sensitization, and CBD's mechanisms in nerve-mediated pain
- CBD Oil for Muscle Spasms — pelvic floor hypertonicity and CBD's antispasmodic mechanisms
References
- Sanchez AM, Vigano P, Floriani I, et al. "The endocannabinoid system in endometriosis: CB1 receptor expression in eutopic and ectopic endometrium and modulation by sex steroids." Human Reproduction. 2016;31(7):1476–1486. PMID: 27165655. [Primary evidence for ECS dysregulation in endometriosis — reduced CB1 expression and altered AEA/FAAH activity.]
- Aviram A, Samuelly-Leichtag G. "Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Pain Physician. 2017;20(6):E755–E796. PMID: 28934780.
- Corroon J, Phillips JA. "A Cross-Sectional Study of Cannabidiol Users." Cannabis and Cannabinoid Research. 2018;3(1):152–161. PMID: 30014050. [62% of CBD users cited anxiety as a primary motivation; broad safety and use survey.]
- Capano A, Weaver R, Burkman E. "Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study." Postgraduate Medicine. 2020;132(1):56–61. PMID: 31711352.
- Russo EB. "Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes." Cannabis and Cannabinoid Research. 2016;1(1):154–165. PMID: 28861491. [Framework for the endo/fibromyalgia/IBS visceral hypersensitivity cluster as CECD.]
- Hammell DC, Zhang LP, Ma F, et al. "Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis." European Journal of Pain. 2016;20(6):936–948. PMID: 26970558. [Establishes pharmacokinetics and anti-inflammatory efficacy of transdermal/topical CBD — supports use of CBD cream for pelvic area application.]
